Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v12-EN Version v11-FR
Language English French
Date Updated 2020-10-27 2020-10-26
Drug Identification Number 02215756 02215756
Brand name CAVERJECT STERILE POWDER CAVERJECT STERILE POWDER
Common or Proper name Caverject Caverject
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients ALPROSTADIL ALPROSTADIL
Strength(s) 23.2MCG 23.2MCG
Dosage form(s) KIT LIQUID POWDER FOR SOLUTION KIT LIQUID POWDER FOR SOLUTION
Route of administration INTRACAVERNOSAL INTRACAVERNOSAL
Packaging size 5 x 20MCG VIALS 5 x 20MCG VIALS
ATC code G04BE G04BE
ATC description OTHER UROLOGICALS, INCL ANTISPASMODICS OTHER UROLOGICALS, INCL ANTISPASMODICS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-10-29 2019-10-29
Estimated end date 2020-10-30 2020-10-30
Actual end date 2020-10-26 2020-10-26
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments This shortage also includes : DIN 02215187 This shortage also includes : DIN 02215187
Health Canada comments